Ledipasvir functions as a nonstructural protein (NS5A) inhibitor for direct-acting antiviral therapy. Viral assembly and replication are disrupted to facilitate a sustained reduction in viral load for affected patients.
Targeting the hepatitis C virus replication cycle, ledipasvir works as an NS5A inhibitor, a class that disrupts viral assembly and release. The molecule appears as the active component in the fixed-dose product Harvoni, which pairs it with sofosbuvir to treat chronic infection. Chemically, it is a large, lipophilic compound with a molecular weight of about 889 g/mol, allowing it to penetrate infected liver cells efficiently. Clinical studies have shown its primary role is to achieve sustained viral suppression when combined with a polymerase inhibitor.
Inside the therapeutic landscape, ledipasvir belongs to the broader family of direct-acting antivirals (DAAs) that revolutionized hepatitis C care by moving away from interferon-based regimens. By focusing on a specific viral protein, this agent reduces treatment length and improves tolerability compared with older approaches. The substance is supplied in a single tablet that contains a fixed amount of both active partners, streamlining dosing for patients.
Incorporated into a single-tablet regimen, ledipasvir appears in the combination product Harvoni, marketed throughout Singapore by authorized distributors. The medication is offered as a film-coated tablet containing 90 mg of ledipasvir and 400 mg of sofosbuvir, intended for oral intake with or without food. Both branded and generic versions may be listed on the Health Sciences Authority’s marketplace, each meeting local quality standards. Tablet strengths do not vary; instead, the fixed composition ensures consistent exposure across patients.
Addressing chronic hepatitis C infection, this compound is employed for adults infected with genotype 1, the most prevalent strain in Singapore. It also benefits patients who have previously received interferon-free therapy but require a potent option to achieve viral clearance. The drug is often prescribed for individuals without decompensated cirrhosis, as its safety profile aligns with outpatient management. In addition, it may be considered for co-infection with HIV when viral suppression is already attained, allowing a streamlined hepatitis C regimen.
Blocking a viral protein essential for the formation of new virus particles, ledipasvir hinders the hepatitis C virus from completing its life cycle inside liver cells. By preventing the virus from assembling correctly, the medication reduces the amount of viral RNA circulating in the bloodstream. This reduction helps the immune system to clear remaining infected cells, leading to a sustained virologic response in most treated individuals.
Reporting mild, transient experiences, patients often note headache or fatigue during the first few weeks of therapy. These symptoms typically resolve without medical intervention and do not require treatment interruption.
Identifying rare but important signals, clinicians watch for severe liver injury, allergic dermatitis, or unexplained jaundice. Immediate medical attention is advised if any of these signs emerge.
Excluding groups where risk outweighs benefit, the drug should not be used in individuals with known hypersensitivity to any component of the tablet. Pregnant or breastfeeding persons are also advised against its use due to limited safety data.
Highlighting broad interaction categories, concurrent use of strong enzyme inducers such as certain anti-epileptics may lower drug exposure, while co-administration with some lipid-lowering agents can increase plasma levels. Patients should reference the specific medication’s insert for a complete interaction list.
Storing the tablets at room temperature away from moisture maintains their stability throughout the prescribed course. Treatment duration typically spans 12 weeks for genotype 1 infection, though shorter courses may apply in selected cases. Formulation differences between brand-name Harvoni and generic equivalents do not affect the dosing schedule. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This overview of ledipasvir provides educational information and does not replace individualized medical guidance. Individual medicines such as Harvoni differ in strength, formulation, and usage instructions, and liability for clinical application rests solely with the prescribing professional. Patients should review the specific medication labeling and consult a qualified healthcare professional for personalized advice.
